# OnCo record i131-mibg (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/i131-mibg/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "i131-mibg" ;
  schema:name "131I-MIBG (iobenguane I-131) therapy"@en ;
  schema:alternateName "Iobenguane I-131 (therapeutic)"@en, "131I-MIBG"@en, "Ultratrace iobenguane"@en, "iobenguane-i-131"@en, "Azedra" ;
  schema:description "High-dose radioactive MIBG delivers radiation from inside neuroblastoma cells that take up noradrenaline; used for relapsed disease and tested in upfront therapy. A branded high-specific-activity form, Azedra, was approved for phaeochromocytoma and paraganglioma in 2018 and discontinued in 2024."@en ;
  schema:url <https://onco.cc/drugs/i131-mibg/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Iobenguane> ;
  owl:sameAs <http://www.wikidata.org/entity/Q27286979> ;
  schema:citation <https://en.wikipedia.org/wiki/Iobenguane>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=iobenguane>, <https://www.cancer.gov/about-cancer/treatment/drugs/iobenguanei131> ;
  onco:status "established" ;
  onco:tag "nci-list" ;
  onco:modality "Radioligand therapy (beta, norepinephrine transporter)" ;
  onco:approval "US 2018: Iobenguane scan-positive unresectable, locally advanced or metastatic phaeochromocytoma or paraganglioma in patients 12 and older (Azedra, high-specific-activity form; discontinued 2024)" ;
  onco:related <https://onco.cc/drugs/lutathera/> ;
  onco:cancers <https://onco.cc/cancers/neuroblastoma/>, <https://onco.cc/cancers/neuroblastoma-high-risk/>, <https://onco.cc/cancers/metastatic-ppgl/>, <https://onco.cc/cancers/neuroendocrine/> ;
  onco:technologies <https://onco.cc/technologies/mibg-theranostics/>, <https://onco.cc/technologies/radioligand-therapy/> ;
  onco:companies <https://onco.cc/companies/lantheus/> ;
  onco:terms <https://onco.cc/terms/radioiodine-term/> ;
  onco:trials <https://onco.cc/trials/anbl1531/> .